Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyloidosis
Biotech
Intellia doesn't need to re-dose NTLA-2001. But it can be done
Intellia Therapeutics doesn’t need to redose patients with a CRISPR gene edited therapy for ATTR amyloidosis. But new data suggests it could be done.
Annalee Armstrong
Jun 25, 2024 3:31pm
Anumana's Pfizer-backed AI algorithm nabs FDA breakthrough tag
Jun 22, 2023 10:29am
Pfizer taps Anumana to build AI cardiac amyloidosis diagnostics
Dec 16, 2022 10:45am
AstraZeneca's wait for data in $3.5B Ionis partnership lengthens
Apr 29, 2022 11:59am
Cedars-Sinai, Stanford develop AI to spot rare heart conditions
Feb 25, 2022 10:10am
Alnylam touts data replication for next-generation Onpattro
Jan 21, 2022 11:40am
